EU Approves AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer
The European Commission approved Enhertu as an adjuvant monotherapy for HER2-positive early breast cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
EU Approves Enhertu as Adjuvant Treatment for Residual HER2-Positive Early Breast Cancer
The approval covers patients with residual disease after neoadjuvant treatment and is based on results from the DESTINY-Breast05 phase 3 trial.